Cervical Cancer
This malignant neoplasm is often caused by persistent infection with certain types of human papillomavirus (HPV).
Early-stage cervical cancer may not cause symptoms, but later-stage disease can lead to abnormal vaginal bleeding, pelvic pain, and other complications.
Effective screening and treatment options are available to help prevent and manage cervical cancer, making it an important area of oncologic research and clinical practice.
Most cited protocols related to «Cervical Cancer»
CIN3+ was chosen as an endpoint instead of cancer because cancer is uncommon in the United States, and risk is profoundly decreased by precursor treatment. Cancers that are found in robust screening programs may represent cancers already prevalent at first screening, rare instances of aggressive or HPV-negative tumors not detectable by screening, or false negative results.24 (link) CIN 3+ was chosen instead of CIN 2+ because it is a more pathologically reproducible diagnosis,25 (link) the HPV type distribution in CIN 3+ lesions more closely approximates that of invasive cervical cancers than the larger range of types found in CIN 2,15 (link)–18 (link),26 (link) and CIN 2 has appreciable regression rates in the absence of treatment.27 (link)–29 (link) The choice of CIN 3+ does have some limitations, as even among CIN 3/AIS lesions, risks of progression to cancer differ. Glandular lesions including AIS, lesions with HPV 16 and 18 infections, and those occurring in older patients have higher cancer risks than HPV-negative lesions and those occurring in younger patients.30 (link)Different nomenclatures for cervical histopathology are in use in the United States. The LAST Project and the WHO recommend a 2-tiered terminology (histologic LSIL/HSIL) for reporting histopathology of HPV-associated squamous lesions, similar to the Bethesda system used for reporting cervical cytology.31 (link),32 However, the CIN nomenclature is still commonly used, and data used to generate this set of guidelines relied on CIN nomenclature. Although no direct correlation is possible without use of the p16 biomarker, histologic HSIL is similar but not identical to CIN 2/3.33 (link)
Human cervical cancer cells HeLa (obtained from ATCC, China), for the fluorescent studies, were obtained from ATCC and cultured in a combination of Eagle’s minimum essential medium (Sigma-Aldrich, China) with 10% fetal bovine serum in an incubator with humidified air or 5% CO2 at 37 °C. Every 3 days media was renewed, and when reaching 90% confluence cells were passed.
Most recents protocols related to «Cervical Cancer»
Example 18
Demonstrating the Selectivity of Stem Cell Derived Neutrophils CKA for Cancer Cells
Neutrophils derived from CD34+ stem cells of three different donors were tested for CKA against both HeLa cells (cervical cancer), PANC-1 cells (pancreatic cancer) as well as non-cancer MCF-12F cells (normal breast epithelial cells).
Similar results were obtained for SCDNs of donors LC252, LC253 and LC254 (
Example 3
A female patient with cervical carcinoma is treated with combined radiation therapy and chemotherapy+NVX-108. Radiation dosage is 45 Gray (Gy) in 20 fractions followed by low dose-rate intracavitary application of 30 Gy to the cervical region. Chemotherapy consists of intravenous cisplatin 40 mg/m2 every week for up to 6 weekly cycles. The patient is administered a bolus IV dose of 0.2 cc/kg NVX-108 (2% w/vol DDFPe) 60 minutes prior to each dose of radiation. Follow-up shows complete response to treatment.
Example 13
Demonstrating CKA of Donor Derived Neutrophils on Different Cancer Cell Types
Neutrophils isolated from five different donors were tested for CKA against both HeLa cells (cervical cancer) and PANC-1 cells (pancreatic cancer).
Example 4
Cells were plated at 6,000 cells/well in a 96-well plate and treated with the indicated concentration of zafirlukast 24 hours later. Cells were allowed to grow for an additional 24 hours before alterations in growth were measured by the PrestoBlue cell proliferation assay in triplicate. Fluorescence readings with an excitation at 570 nm and emission of 600 nm were collected and treated samples were converted to a percentage of the untreated controls.
OVCar8 (human ovarian cancer cell line), HCT116 (human colon cancer), HeLa (cervical cancer cell line) and MDA-MB-231 (breast cancer cell line) cell lines were examined for their ability to inhibit cell proliferation. OVCar8 and HCT116 cells exhibited an IC50 in the 5-10 μM range. HeLa cervical cancer cells and MDA-MB-231 breast cancer lines were less sensitive. Table 1 illustrates the results of a cell proliferation assay testing zafirlukast against OVCar8 cells, HCT116 cells, HeLa cells and MDA-MB-231 cells.
This retrospective study was conducted in accordance with the principles embodied in the 1964 Declaration of Helsinki and was approved by the Ethics Committee of the Union Hospital of the Huazhong University of Science and Technology (20220023). Informed consent was obtained from all the participants or their legal guardians if the participants cannot write.
Top products related to «Cervical Cancer»
More about "Cervical Cancer"
This form of cancer is often caused by persistent infection with certain types of human papillomavirus (HPV), a common sexually transmitted virus.
In the early stages, cervical cancer may not produce any symptoms, but as the disease progresses, it can lead to abnormal vaginal bleeding, pelvic pain, and other complications.
Effective screening and treatment options are available to help prevent and manage cervical cancer, making it an important area of oncologic research and clinical practice.
Screening methods like Pap smears and HPV tests can detect precancerous changes in the cervix, allowing for early intervention and prevention.
Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches, depending on the stage and severity of the cancer.
Researchers continue to explore various aspects of cervical cancer, such as the role of cell culture models like CaSki and MCF-7 cells, as well as the use of media like RPMI 1640 and DMEM to support cancer cell growth and study.
Additionally, techniques like Lipofectamine 2000 transfection are employed to investigate gene expression and cellular mechanisms in cervical cancer cells.
Understanding the complexities of cervical cancer and the advancements in its prevention and management is crucial for healthcare professionals, researchers, and the general public.
By staying informed about the latest developments in this field, we can work towards reducing the burden of this disease and improving outcomes for those affected.